

CLAIMS

1. Use of a type I IFN receptor (IFNAR1) inhibitor in the preparation of a medicament for the treatment of treatment-refractory systemic lupus erythematosus (SLE) in a patient in need thereof, wherein the IFNAR1 inhibitor is anifrolumab.
2. The use of claim 1, wherein the patient has previously received prior treatment with glucocorticoids, antimalarials and/or immunosuppressants.
3. The use of claim 1 or 2, wherein pre-treatment the patient has a SLEDAI-2K score of ≥ 6 , ≥ 1 A and/or a ≥ 2 B BILAG-2004 organ domain score, and/or a Physician's Global Assessment of ≥ 1 .
4. The use of any preceding claim, wherein the patient has received prior treatment with azathioprine, mizoribine, mycophenolate mofetil, mycophenolic acid, and/or methotrexate.
5. The use of any preceding claim, wherein the patient has moderate to severe SLE.
6. The use of any preceding claim, wherein the medicament comprises a fixed dose of anifrolumab.
7. The use of any preceding claim, wherein the medicament comprises 300 mg to 1000 mg of anifrolumab.
8. The use of any preceding claim, wherein the medicament comprises 300 mg anifrolumab.
9. The use of any of claims 1 to 6, wherein the medicament comprises 120 mg anifrolumab.
10. The use of any of preceding claim, wherein the medicament is for subcutaneous administration to the patient.
11. The use of any of preceding claim, wherein the medicament is for subcutaneous administration to the patient once a week.
12. The use of any of preceding claim, wherein the medicament is for subcutaneous administration of 120 mg anifrolumab to the patient once a week.
13. The use of any of claims 1 to 8, wherein the medicament is for intravenous administration.
14. The use of any of claims 1 to 8, wherein the medicament is for intravenous administration to the patient once every four weeks (Q4W).
15. The use of any of claims 1 to 8, wherein the medicament is for intravenous administration of 300 mg anifrolumab to the patient Q4W.